MSD – one of the leading investors in clinical research in Denmark
Through clinical trials, and a strong collaboration between MSD, doctors and nurses, we ensure that our innovations are built on solid evidence and science. Behind every single study lies a hope for a better life for patients throughout the world
Denmark: A strong foundation
MSD employs over 50 persons in Denmark working directly with clinical trials. In addition, MSD invests around DKK 130 million (EUR 17,2 million) in the Danish life science ecosystem. What makes Denmark stand out? A powerful mix of world-class hospitals, talented researchers and agile regulatory framework.
In recent years, the Danish government has taken active steps to boost the life science industry even further by building on the already strong national healthcare system and strong environment for business and science. This also includes a keen political focus on continuously improving the framework conditions for conducting clinical trials in Denmark.
Denmark has recently cut phase I trial approval times for mono national trials to just 14 days, among the fastest in Europe! Combine that with strong tradition of public-private partnerships and a digital health system second to none, you get a recipe that attracts global pharma companies to research and launch treatments here first.
MSD’s long-term commitment
Denmark has a strong foundation when competing with other countries in terms of attracting foreign investments in Life Science. This is not least the case in areas of clinical research and collecting real world evidence. The high-quality data, excellent collaboration between public and private stakeholders, and a willingness to ensure rapid access to new innovative treatments for patients are among the most important reasons for our long-term commitment to investing in clinical research in Denmark. There are some challenges for our industry in Europe, including Denmark.
Europe needs to streamline its processes and cooperation, to truly achieve its aim of creating a one stop shop for multi-country studies, allowing medicine developers in Europe to scale and compete with the US, China, Japan and other leading regions. MSD Denmark therefore supports Denmark’s ambition to strengthen European life science frameworks focused on innovation and disease prevention, making sure Europe and Denmark remain attractive for clinical research investment in the future.
Trial Nation: one entry, endless possibilities
A big part of Denmark’s appeal lies in Trial Nation, a public-private partnership offering a single national entry point for life science companies, patient organisations and clinical researchers wishing to sponsor, participate in, and conduct clinical trials in Denmark. MSD has been an active member for many years, benefitting from Trial Nation’s facilitation of easy access to a network of clinical research units at the Danish hospitals within all disease areas, free of charge.
This ensures a quick and efficient pre-feasibility and feasibility process, as well as a good dialogue about designing the best possible framework for cooperation between the hospitals and companies wishing to conduct clinical trials in Denmark.
Invest in Denmark: your partner in progress
Together with Trial Nation, Invest in Denmark of the Danish Ministry of Foreign Affairs works to attract clinical trials for the benefit of patients and healthcare providers. From facilitating high-level meetings at conferences such as ASCO and ID-Week, to connecting with Danish clinicians, the collaboration is all about ensuring that foreign life sciences companies like MSD help Denmark stay at the cutting edge of clinical research.
"The commitment of MSD to the Danish healthcare sector is extremely valued . It is a testament to our competitive life science cluster as well as to the Danish government’s consistent focus on improving framework conditions for conducting clinical trials and research for the benefit of patients."
